CVRX Overview

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is12.50 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CVRx Inc revenue for the last quarter amounts to 16.02M USD, increased 4.45

CVRx Inc. EPS for the last quarter amounts to -0.46 USD, increased 6.98

CVRx Inc (CVRX) has 223 emplpoyees as of March 17 2026.

Today CVRX has the market capitalization of 207.07M USD.